Press release from Companies: Första patienten i behandling i RhoVacs kliniska fas IIb-studie i Storbritannien

Press release from Companies: RhoVac’s Prostate Cancer Drug Candidate, RV001, is granted Fast Track Designation by the FDA

Press release from Companies: RhoVacs läkemedelskandidat för prostatacancer, RV001, beviljas Fast Track Designation av FDA

Press release from Companies: Komplettering: Positiva Resultat från RhoVacs kliniska fas I/II-studie publicerade i Journal for ImmunoTherapy of Cancer

Press release from Companies: Positive Results from RhoVac's Clinical Phase I/II Study published in Journal of ImmunoTherapy of Cancer

Press release from Companies: Positiva resultat från RhoVacs kliniska fas I/II-studie publicerade i Journal for ImmunoTherapy of Cancer

Reports: RhoVac AB presenterar delårsrapport Q3 2020

More from the company: RhoVac Participates in BIO Europe Digital

More from the company: RhoVac deltar i BIO Europe Digital

Press release from Companies: Article on RhoVac’s Phase I/II study to be published in November

Press release from Companies: Artikel om RhoVacs fas I/II-studie kommer att publiceras i november

Press release from Companies: The Covid-19 pandemic is expected to further affect RhoVac’s clinical phase IIb study